Ligand Pharmaceuticals (LGND) Projected to Announce Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is expected to release its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of $2.33 per share and revenue of $77.00 million for the quarter. Ligand Pharmaceuticals has set its FY 2026 guidance at 9.000-9.500 EPS. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $2.37 EPS for the quarter, beating the consensus estimate of $1.97 by $0.40. The firm had revenue of $63.69 million during the quarter, compared to analyst estimates of $61.30 million. The firm’s revenue for the quarter was up 33.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.60 EPS. On average, analysts expect Ligand Pharmaceuticals to post $5.25 EPS for the current fiscal year and $8.35 EPS for the next fiscal year.

Ligand Pharmaceuticals Trading Down 0.4%

NASDAQ LGND traded down $1.17 during trading hours on Wednesday, reaching $310.56. 8,226 shares of the company’s stock were exchanged, compared to its average volume of 266,355. The stock has a market cap of $6.19 billion, a PE ratio of 33.42 and a beta of 1.14. The firm has a fifty day moving average of $294.53 and a 200-day moving average of $250.58. Ligand Pharmaceuticals has a one year low of $175.89 and a one year high of $326.63.

Insider Transactions at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, Director Jason Haas sold 7,138 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $292.81, for a total transaction of $2,090,077.78. Following the sale, the director owned 3,981 shares in the company, valued at $1,165,676.61. This represents a 64.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Octavio Espinoza sold 31,641 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $292.06, for a total value of $9,241,070.46. Following the transaction, the chief financial officer directly owned 27,696 shares of the company’s stock, valued at $8,088,893.76. The trade was a 53.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 54,979 shares of company stock worth $16,068,898. Insiders own 5.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Leerink Partners started coverage on Ligand Pharmaceuticals in a report on Friday, August 14th. They issued an “outperform” rating and a $330.00 price target on the stock. Stifel Nicolaus increased their price objective on shares of Ligand Pharmaceuticals from $255.00 to $332.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Royal Bank Of Canada raised their price target on shares of Ligand Pharmaceuticals from $340.00 to $345.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. HC Wainwright restated a “buy” rating and set a $358.00 price objective on shares of Ligand Pharmaceuticals in a research report on Thursday, September 24th. Finally, Oppenheimer restated an “outperform” rating and set a $326.00 price target (up from $285.00) on shares of Ligand Pharmaceuticals in a report on Monday, August 3rd. Ten research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, Ligand Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $337.89.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biopharmaceutical company that develops, acquires and licenses technologies intended to improve the development and commercialization of medicines. Rather than operating primarily as a traditional drug manufacturer, Ligand generally works with pharmaceutical and biotechnology partners, receiving licensing payments, royalties and other consideration tied to partnered products.

The company’s principal technology is Captisol, a modified cyclodextrin designed to improve the solubility, stability and delivery of certain active pharmaceutical ingredients.